PSTX - Poseida Therapeutics, Inc. Stock Price, Fair Value and News

$9.50

Market Closed

PSTX Stock Valuation Analysis

Valuation

Max Portfolio %

PSTX Price Action

PSTX RSI Chart

PSTX Stock Valuation Analysis

Valuation

Max Portfolio %

PSTX Valuation

PSTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PSTX Fundamentals

PSTX Revenue

PSTX Earnings

PSTX Profitability

PSTX Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	82.5M	88.5M	150.9M	0
2023	139.4M	156.7M	49.8M	64.7M
2022	56.1M	80.9M	105.7M	130.5M
2021	0	0	0	31.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

CEO	Mr. Mark J. Gergen J.D.
WEBSITE	https://poseida.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	348